Caregen（A214370）株式概要バイオテクノロジー企業であるCaregen Co, Ltd.は、生物模倣ペプチドの研究、開発、商業化を世界中で行っている。 詳細A214370 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績1/6財務の健全性6/6配当金0/6リスク分析過去5年間で収益は年間0.8%減少しました。 KR市場と比較した過去 3 か月間の株価の変動すべてのリスクチェックを見るA214370 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW479,227 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA479,227 investors already sharing narrativesYour Fair Value₩Current Price₩66.80k5.5% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture099b2016201920222025202620282031Revenue ₩99.1bEarnings ₩31.2bAdvancedSet Fair ValueView all narrativesCaregen Co., Ltd. 競合他社Hanmi PharmSymbol: KOSE:A128940Market cap: ₩5.0tST PharmLtdSymbol: KOSDAQ:A237690Market cap: ₩2.1tYuhanSymbol: KOSE:A000100Market cap: ₩5.8tDaewoong PharmaceuticalSymbol: KOSE:A069620Market cap: ₩1.5t価格と性能株価の高値、安値、推移の概要Caregen過去の株価現在の株価₩66,000.0052週高値₩153,800.0052週安値₩44,400.00ベータ1.071ヶ月の変化8.02%3ヶ月変化-34.85%1年変化37.93%3年間の変化62.56%5年間の変化360.89%IPOからの変化208.41%最新ニュースNew Risk • May 21New major risk - Revenue and earnings growthEarnings have declined by 0.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.8% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (13% average weekly change).お知らせ • Apr 25Caregen Co., Ltd. to Report Q1, 2026 Results on Apr 30, 2026Caregen Co., Ltd. announced that they will report Q1, 2026 results on Apr 30, 2026Reported Earnings • Mar 20Full year 2025 earnings released: EPS: ₩411 (vs ₩658 in FY 2024)Full year 2025 results: EPS: ₩411 (down from ₩658 in FY 2024). Revenue: ₩72.8b (down 12% from FY 2024). Net income: ₩20.1b (down 38% from FY 2024). Profit margin: 28% (down from 39% in FY 2024). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 45% per year, which means it is well ahead of earnings.お知らせ • Mar 10Caregen Co., Ltd., Annual General Meeting, Mar 24, 2026Caregen Co., Ltd., Annual General Meeting, Mar 24, 2026, at 09:30 Tokyo Standard Time. Location: conference room, 24, yeongdong-daero 65-gil, gangnam-gu, seoul South KoreaNew Risk • Jan 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.New Risk • Nov 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.最新情報をもっと見るRecent updatesNew Risk • May 21New major risk - Revenue and earnings growthEarnings have declined by 0.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.8% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (13% average weekly change).お知らせ • Apr 25Caregen Co., Ltd. to Report Q1, 2026 Results on Apr 30, 2026Caregen Co., Ltd. announced that they will report Q1, 2026 results on Apr 30, 2026Reported Earnings • Mar 20Full year 2025 earnings released: EPS: ₩411 (vs ₩658 in FY 2024)Full year 2025 results: EPS: ₩411 (down from ₩658 in FY 2024). Revenue: ₩72.8b (down 12% from FY 2024). Net income: ₩20.1b (down 38% from FY 2024). Profit margin: 28% (down from 39% in FY 2024). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 45% per year, which means it is well ahead of earnings.お知らせ • Mar 10Caregen Co., Ltd., Annual General Meeting, Mar 24, 2026Caregen Co., Ltd., Annual General Meeting, Mar 24, 2026, at 09:30 Tokyo Standard Time. Location: conference room, 24, yeongdong-daero 65-gil, gangnam-gu, seoul South KoreaNew Risk • Jan 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.New Risk • Nov 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.分析記事 • Nov 23There's Reason For Concern Over Caregen Co., Ltd.'s (KOSDAQ:214370) Massive 32% Price JumpDespite an already strong run, Caregen Co., Ltd. ( KOSDAQ:214370 ) shares have been powering on, with a gain of 32% in...分析記事 • Sep 12Subdued Growth No Barrier To Caregen Co., Ltd. (KOSDAQ:214370) With Shares Advancing 26%Despite an already strong run, Caregen Co., Ltd. ( KOSDAQ:214370 ) shares have been powering on, with a gain of 26% in...New Risk • Sep 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • Jul 30Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩50,400, the stock trades at a trailing P/E ratio of 78.9x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 90% over the past three years.Valuation Update With 7 Day Price Move • Jul 15Investor sentiment improves as stock rises 28%After last week's 28% share price gain to ₩48,200, the stock trades at a trailing P/E ratio of 75.4x. Average trailing P/E is 18x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 159% over the past three years.分析記事 • Jul 14Caregen Co., Ltd.'s (KOSDAQ:214370) 30% Jump Shows Its Popularity With InvestorsCaregen Co., Ltd. ( KOSDAQ:214370 ) shares have continued their recent momentum with a 30% gain in the last month...分析記事 • Jul 14Why Investors Shouldn't Be Surprised By Caregen Co., Ltd.'s (KOSDAQ:214370) 30% Share Price SurgeCaregen Co., Ltd. ( KOSDAQ:214370 ) shares have continued their recent momentum with a 30% gain in the last month...New Risk • Jul 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Dividend is not well covered by earnings and cash flows. Payout ratio: 100% Paying a dividend despite having no free cash flows. High level of non-cash earnings (73% accrual ratio).Upcoming Dividend • Jun 20Upcoming dividend of ₩240 per shareEligible shareholders must have bought the stock before 27 June 2025. Payment date: 21 July 2025. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 2.0%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (1.0%).分析記事 • May 22Caregen's (KOSDAQ:214370) Problems Go Beyond Weak ProfitThe market rallied behind Caregen Co., Ltd.'s ( KOSDAQ:214370 ) stock, leading do a rise in the share price after its...New Risk • May 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 97% Paying a dividend despite having no free cash flows. High level of non-cash earnings (63% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).Buy Or Sell Opportunity • May 12Now 25% overvaluedOver the last 90 days, the stock has fallen 1.5% to ₩30,550. The fair value is estimated to be ₩24,440, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 33%. Revenue is forecast to grow by 44% in 2 years. Earnings are forecast to grow by 89% in the next 2 years.Board Change • Apr 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 1 highly experienced director. Independent Outside Director Seong-Wook Heo was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Mar 21Full year 2024 earnings: EPS misses analyst expectationsFull year 2024 results: EPS: ₩658 (down from ₩813 in FY 2023). Revenue: ₩82.6b (up 4.3% from FY 2023). Net income: ₩32.3b (down 19% from FY 2023). Profit margin: 39% (down from 50% in FY 2023). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.9%. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.お知らせ • Mar 12Caregen Co., Ltd., Annual General Meeting, Mar 25, 2025Caregen Co., Ltd., Annual General Meeting, Mar 25, 2025, at 09:30 Tokyo Standard Time. Location: conference room, 16-27, ls-ro 91beon-gil, dongan-gu, gyeonggi-do, anyang South Korea分析記事 • Mar 08Caregen Co., Ltd. (KOSDAQ:214370) May Have Run Too Fast Too Soon With Recent 26% Price PlummetCaregen Co., Ltd. ( KOSDAQ:214370 ) shares have retraced a considerable 26% in the last month, reversing a fair amount...New Risk • Feb 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 121% Paying a dividend despite having no free cash flows. High level of non-cash earnings (68% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).Buy Or Sell Opportunity • Feb 06Now 32% overvalued after recent price riseOver the last 90 days, the stock has risen 101% to ₩33,950. The fair value is estimated to be ₩25,767, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 28%. Revenue is forecast to grow by 45% in 2 years. Earnings are forecast to grow by 61% in the next 2 years.お知らせ • Feb 03Caregen Co., Ltd. to Report Q4, 2024 Results on Feb 10, 2025Caregen Co., Ltd. announced that they will report Q4, 2024 results on Feb 10, 2025分析記事 • Jan 20A Look At The Fair Value Of Caregen Co., Ltd. (KOSDAQ:214370)Key Insights Using the 2 Stage Free Cash Flow to Equity, Caregen fair value estimate is ₩25,767 Caregen's ₩28,100 share...Buy Or Sell Opportunity • Jan 03Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 62% to ₩31,750. The fair value is estimated to be ₩25,767, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 28%. Revenue is forecast to grow by 45% in 2 years. Earnings are forecast to grow by 61% in the next 2 years.Valuation Update With 7 Day Price Move • Dec 26Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩28,500, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 17x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 126% over the past three years.分析記事 • Dec 20Earnings Not Telling The Story For Caregen Co., Ltd. (KOSDAQ:214370) After Shares Rise 29%Caregen Co., Ltd. ( KOSDAQ:214370 ) shares have continued their recent momentum with a 29% gain in the last month...Valuation Update With 7 Day Price Move • Nov 21Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₩23,150, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 17x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 86% over the past three years.分析記事 • Nov 21Why Caregen's (KOSDAQ:214370) Shaky Earnings Are Just The Beginning Of Its ProblemsDespite Caregen Co., Ltd.'s ( KOSDAQ:214370 ) recent earnings report having lackluster headline numbers, the market...お知らせ • Nov 08Caregen Co., Ltd. to Report Q3, 2024 Results on Nov 11, 2024Caregen Co., Ltd. announced that they will report Q3, 2024 results on Nov 11, 2024Valuation Update With 7 Day Price Move • Sep 13Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩18,550, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 19x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 33% over the past three years.New Risk • Aug 26New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. Payout ratio: 93% The company is paying a dividend despite having no free cash flows. Dividend yield: 5.2% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 93% Paying a dividend despite having no free cash flows. High level of non-cash earnings (70% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).Major Estimate Revision • Aug 06Consensus EPS estimates fall by 18%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from ₩93.0m to ₩85.1m. EPS estimate also fell from ₩907 per share to ₩747 per share. Net income forecast to grow 9.7% next year vs 21% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target down from ₩24,000 to ₩14,000. Share price fell 29% to ₩16,240 over the past week.分析記事 • Aug 06Why We're Not Concerned Yet About Caregen Co., Ltd.'s (KOSDAQ:214370) 26% Share Price PlungeThe Caregen Co., Ltd. ( KOSDAQ:214370 ) share price has fared very poorly over the last month, falling by a substantial...Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 28%After last week's 28% share price decline to ₩16,240, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 16x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 21% over the past three years.New Risk • Aug 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (62% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.3% average weekly change).お知らせ • Aug 01Caregen Co., Ltd. to Report First Half, 2024 Results on Aug 02, 2024Caregen Co., Ltd. announced that they will report first half, 2024 results on Aug 02, 2024Reported Earnings • May 18First quarter 2024 earnings released: EPS: ₩194 (vs ₩288 in 1Q 2023)First quarter 2024 results: EPS: ₩194 (down from ₩288 in 1Q 2023). Revenue: ₩20.4b (down 17% from 1Q 2023). Net income: ₩9.52b (down 33% from 1Q 2023). Profit margin: 47% (down from 57% in 1Q 2023). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 19% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • May 01Caregen Co., Ltd. to Report Q1, 2024 Results on May 10, 2024Caregen Co., Ltd. announced that they will report Q1, 2024 results on May 10, 2024分析記事 • Mar 18Caregen (KOSDAQ:214370) Posted Healthy Earnings But There Are Some Other Factors To Be Aware OfCaregen Co., Ltd. ( KOSDAQ:214370 ) just reported some strong earnings, and the market reacted accordingly with a...Reported Earnings • Mar 15Full year 2023 earnings released: EPS: ₩813 (vs ₩556 in FY 2022)Full year 2023 results: EPS: ₩813 (up from ₩556 in FY 2022). Revenue: ₩79.2b (up 15% from FY 2022). Net income: ₩39.9b (up 46% from FY 2022). Profit margin: 50% (up from 40% in FY 2022). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 43% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Mar 12Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩26,200, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 15x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 111% over the past three years.分析記事 • Mar 05With Caregen Co., Ltd. (KOSDAQ:214370) It Looks Like You'll Get What You Pay ForCaregen Co., Ltd.'s ( KOSDAQ:214370 ) price-to-earnings (or "P/E") ratio of 29.7x might make it look like a strong sell...Valuation Update With 7 Day Price Move • Feb 13Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩25,350, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 16x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 92% over the past three years.Upcoming Dividend • Dec 20Upcoming dividend of ₩340 per share at 2.0% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 05 April 2024. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 2.0%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.1%).Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: ₩199 (vs ₩128 in 3Q 2022)Third quarter 2023 results: EPS: ₩199 (up from ₩128 in 3Q 2022). Revenue: ₩18.7b (up 2.2% from 3Q 2022). Net income: ₩9.80b (up 56% from 3Q 2022). Profit margin: 52% (up from 34% in 3Q 2022). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 41% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Pharmaceuticals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Nov 13Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₩24,000, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 13x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 101% over the past three years.お知らせ • Nov 01Caregen Co., Ltd. to Report Q3, 2023 Results on Nov 10, 2023Caregen Co., Ltd. announced that they will report Q3, 2023 results on Nov 10, 2023Valuation Update With 7 Day Price Move • Oct 10Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₩31,400, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 15x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 176% over the past three years.Buying Opportunity • Sep 18Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 14%. The fair value is estimated to be ₩50,401, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.2% over the last 3 years. Earnings per share has declined by 29%. Revenue is forecast to grow by 123% in 2 years. Earnings is forecast to grow by 153% in the next 2 years.Price Target Changed • Aug 25Price target increased by 7.4% to ₩58,000Up from ₩54,000, the current price target is provided by 1 analyst. New target price is 48% above last closing price of ₩39,250. Stock is up 56% over the past year. The company is forecast to post earnings per share of ₩946 for next year compared to ₩278 last year.お知らせ • Jul 29Caregen Co., Ltd. to Report Q2, 2023 Results on Aug 09, 2023Caregen Co., Ltd. announced that they will report Q2, 2023 results on Aug 09, 2023Buying Opportunity • Jul 03Now 24% undervaluedOver the last 90 days, the stock is up 10.0%. The fair value is estimated to be ₩310,506, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.9% over the last 3 years. Earnings per share has declined by 30%. Revenue is forecast to grow by 139% in 2 years. Earnings is forecast to grow by 171% in the next 2 years.Upcoming Dividend • Jun 22Upcoming dividend of ₩1,000 per share at 1.2% yieldEligible shareholders must have bought the stock before 29 June 2023. Payment date: 20 July 2023. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 1.2%. Lower than top quartile of South Korean dividend payers (3.2%). In line with average of industry peers (1.2%).New Risk • Jun 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 156% Cash payout ratio: 119% Minor Risk Share price has been volatile over the past 3 months (8.3% average weekly change).Valuation Update With 7 Day Price Move • Jun 16Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩227,500, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 12x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 233% over the past three years.Reported Earnings • May 10First quarter 2023 earnings released: EPS: ₩1,440 (vs ₩768 in 1Q 2022)First quarter 2023 results: EPS: ₩1,440 (up from ₩768 in 1Q 2022). Revenue: ₩24.7b (up 61% from 1Q 2022). Net income: ₩14.1b (up 88% from 1Q 2022). Profit margin: 57% (up from 49% in 1Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has increased by 54% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩213,500, the stock trades at a trailing P/E ratio of 76.9x. Average trailing P/E is 20x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 117% over the past year.Valuation Update With 7 Day Price Move • Mar 21Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩201,500, the stock trades at a trailing P/E ratio of 72.6x. Average trailing P/E is 20x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 249% over the past year.Reported Earnings • Mar 18Full year 2022 earnings released: EPS: ₩2,778 (vs ₩2,582 in FY 2021)Full year 2022 results: EPS: ₩2,778 (up from ₩2,582 in FY 2021). Revenue: ₩69.1b (up 17% from FY 2021). Net income: ₩27.3b (up 7.7% from FY 2021). Profit margin: 40% (down from 43% in FY 2021). The decrease in margin was driven by higher expenses.Valuation Update With 7 Day Price Move • Feb 01Investor sentiment improves as stock rises 28%After last week's 28% share price gain to ₩180,000, the stock trades at a trailing P/E ratio of 68.7x. Average trailing P/E is 20x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 189% over the past year.Valuation Update With 7 Day Price Move • Dec 27Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₩145,000, the stock trades at a trailing P/E ratio of 55.4x. Average trailing P/E is 21x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 126% over the past year.Upcoming Dividend • Dec 21Upcoming dividend of ₩1,500 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 17 April 2023. The company is paying out more than 100% of its profits and is paying out 75% of its cash flow. Trailing yield: 2.0%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (1.0%).Valuation Update With 7 Day Price Move • Dec 05Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₩128,100, the stock trades at a trailing P/E ratio of 48.9x. Average trailing P/E is 19x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 104% over the past year.Reported Earnings • Nov 16Third quarter 2022 earnings released: EPS: ₩640 (vs ₩669 in 3Q 2021)Third quarter 2022 results: EPS: ₩640 (down from ₩669 in 3Q 2021). Revenue: ₩18.3b (up 34% from 3Q 2021). Net income: ₩6.28b (down 4.3% from 3Q 2021). Profit margin: 34% (down from 48% in 3Q 2021). The decrease in margin was driven by higher expenses.Reported Earnings • Nov 13Third quarter 2022 earnings released: EPS: ₩640 (vs ₩669 in 3Q 2021)Third quarter 2022 results: EPS: ₩640 (down from ₩669 in 3Q 2021). Revenue: ₩18.3b (up 34% from 3Q 2021). Net income: ₩6.28b (down 4.3% from 3Q 2021). Profit margin: 34% (down from 48% in 3Q 2021). The decrease in margin was driven by higher expenses.Valuation Update With 7 Day Price Move • Nov 07Investor sentiment improved over the past weekAfter last week's 27% share price gain to ₩116,900, the stock trades at a trailing P/E ratio of 44.1x. Average trailing P/E is 21x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 80% over the past year.Valuation Update With 7 Day Price Move • Oct 21Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩95,600, the stock trades at a trailing P/E ratio of 36x. Average trailing P/E is 20x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 40% over the past year.Valuation Update With 7 Day Price Move • Sep 28Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩119,400, the stock trades at a trailing P/E ratio of 45x. Average trailing P/E is 19x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 73% over the past year.Valuation Update With 7 Day Price Move • Sep 06Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩144,400, the stock trades at a trailing P/E ratio of 54.4x. Average trailing P/E is 22x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 98% over the past year.Valuation Update With 7 Day Price Move • Jul 20Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩110,500, the stock trades at a trailing P/E ratio of 43.1x. Average trailing P/E is 22x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 68% over the past year.Upcoming Dividend • Jun 22Upcoming dividend of ₩800 per shareEligible shareholders must have bought the stock before 29 June 2022. Payment date: 20 July 2022. Payout ratio is on the higher end at 90%, however this is supported by cash flows. Trailing yield: 2.5%. Lower than top quartile of South Korean dividend payers (3.2%). Higher than average of industry peers (1.0%).Valuation Update With 7 Day Price Move • May 06Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to ₩104,000, the stock trades at a trailing P/E ratio of 40.3x. Average trailing P/E is 27x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 71% over the past year.Valuation Update With 7 Day Price Move • Apr 13Investor sentiment improved over the past weekAfter last week's 31% share price gain to ₩126,000, the stock trades at a trailing P/E ratio of 48.8x. Average trailing P/E is 26x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 82% over the past three years.Valuation Update With 7 Day Price Move • Mar 29Investor sentiment improved over the past weekAfter last week's 40% share price gain to ₩97,200, the stock trades at a trailing P/E ratio of 37.6x. Average trailing P/E is 25x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 40% over the past three years.Valuation Update With 7 Day Price Move • Mar 15Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩65,000, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 23x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 6.1% over the past three years.Upcoming Dividend • Dec 22Upcoming dividend of ₩1,300 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 11 April 2022. Payout ratio is on the higher end at 87%, however this is supported by cash flows. Trailing yield: 2.4%. Within top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.8%).Upcoming Dividend • Jun 23Upcoming dividend of ₩700 per shareEligible shareholders must have bought the stock before 29 June 2021. Payment date: 24 July 2021. Trailing yield: 3.0%. Within top quartile of South Korean dividend payers (2.1%). Higher than average of industry peers (0.6%).分析記事 • Apr 20A Look At The Fair Value Of Caregen Co., Ltd. (KOSDAQ:214370)In this article we are going to estimate the intrinsic value of Caregen Co., Ltd. ( KOSDAQ:214370 ) by taking the...分析記事 • Mar 02Here's How We Evaluate Caregen Co., Ltd.'s (KOSDAQ:214370) DividendDividend paying stocks like Caregen Co., Ltd. ( KOSDAQ:214370 ) tend to be popular with investors, and for good reason...分析記事 • Feb 04Caregen (KOSDAQ:214370) Is Growing Earnings But Are They A Good Guide?Statistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. However...お知らせ • Jan 31Caregen Co., Ltd. to Report Fiscal Year 2020 Results on Feb 10, 2021Caregen Co., Ltd. announced that they will report fiscal year 2020 results on Feb 10, 2021分析記事 • Jan 14Do Its Financials Have Any Role To Play In Driving Caregen Co., Ltd.'s (KOSDAQ:214370) Stock Up Recently?Most readers would already be aware that Caregen's (KOSDAQ:214370) stock increased significantly by 28% over the past...Is New 90 Day High Low • Jan 05New 90-day high: ₩76,300The company is up 23% from its price of ₩62,200 on 07 October 2020. The South Korean market is also up 23% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Pharmaceuticals industry, which is up 16% over the same period.分析記事 • Dec 25Caregen Co., Ltd. (KOSDAQ:214370) Goes Ex-Dividend SoonIt looks like Caregen Co., Ltd. ( KOSDAQ:214370 ) is about to go ex-dividend in the next three days. Ex-dividend means...分析記事 • Dec 10Do Insiders Own Lots Of Shares In Caregen Co., Ltd. (KOSDAQ:214370)?Every investor in Caregen Co., Ltd. ( KOSDAQ:214370 ) should be aware of the most powerful shareholder groups...Is New 90 Day High Low • Dec 09New 90-day high: ₩71,400The company is up 11% from its price of ₩64,100 on 10 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 6.0% over the same period.Is New 90 Day High Low • Nov 20New 90-day high: ₩66,400The company is up 8.0% from its price of ₩61,700 on 21 August 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 5.0% over the same period.分析記事 • Nov 19Is Caregen Co., Ltd. (KOSDAQ:214370) A Great Dividend Stock?Could Caregen Co., Ltd. (KOSDAQ:214370) be an attractive dividend share to own for the long haul? Investors are often...Is New 90 Day High Low • Oct 15New 90-day low: ₩60,400The company is down 14% from its price of ₩69,900 on 17 July 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 12% over the same period.株主還元A214370KR PharmaceuticalsKR 市場7D18.7%10.3%-4.2%1Y37.9%-8.0%84.8%株主還元を見る業界別リターン: A214370過去 1 年間で-8 % の収益を上げたKR Pharmaceuticals業界を上回りました。リターン対市場: A214370は、過去 1 年間で84.8 % のリターンを上げたKR市場を下回りました。価格変動Is A214370's price volatile compared to industry and market?A214370 volatilityA214370 Average Weekly Movement14.1%Pharmaceuticals Industry Average Movement7.2%Market Average Movement9.9%10% most volatile stocks in KR Market17.8%10% least volatile stocks in KR Market5.2%安定した株価: A214370の株価は、 KR市場と比較して過去 3 か月間で変動しています。時間の経過による変動: A214370の weekly volatility ( 14% ) は過去 1 年間安定していますが、依然としてKRの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2001193Yong-Ji Jeongcaregen.co.krバイオテクノロジー企業であるCaregen Co, Ltd.は、生物模倣ペプチドの研究、開発、商業化を世界中で行っている。同社はフィラー製品を「REVOFIL」、「DR.CYJ」、「PROSTROLANE」、「PROSTROLANE B-Series」、「CG Styler 600」の名称で、スキンケア製品を「Dermaheal」、「PURILUX whitening」、「Pim-Pim-Paul」、「Neovert」の名称で、スカルプケア製品を「Renokin」、「Pelo Baum」の名称で、健康食品を「proGsterol」の名称で提供している。また、COVID-19治療薬、湿性黄斑変性症治療薬、乾性黄斑変性症治療薬、抗ウイルス薬、糖尿病網膜症治療薬、白内障治療薬、多汗症治療薬、鎮痛薬、脱毛症治療薬、肥満症治療薬、乾癬治療薬、創傷治療薬、関節炎治療薬、鼻炎治療薬、美顔、頭皮・頭髪改善、ボディケア、関節炎治療などの医療機器も開発している；シワ改善、美白、頭皮・毛髪改善、ニキビケア、UVカット、アトピー改善、微細ダストブロック、クマ改善、セルライト減少、皮脂分泌コントロールなどの化粧品、血糖値コントロール、肝機能改善、二日酔い治療、コレステロールコントロール、体脂肪減少などの食品。ケアゲン社は2001年に設立され、韓国の安養市に本社を置いている。もっと見るCaregen Co., Ltd. 基礎のまとめCaregen の収益と売上を時価総額と比較するとどうか。A214370 基礎統計学時価総額₩3.23t収益（TTM）₩23.36b売上高(TTM)₩74.22b138.1xPER（株価収益率43.5xP/SレシオA214370 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計A214370 損益計算書（TTM）収益₩74.22b売上原価₩21.28b売上総利益₩52.94bその他の費用₩29.58b収益₩23.36b直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）478.06グロス・マージン71.33%純利益率31.48%有利子負債／自己資本比率0%A214370 の長期的なパフォーマンスは？過去の実績と比較を見る配当金0.6%現在の配当利回り110%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/09 23:09終値2026/08/07 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Caregen Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8 アナリスト機関Byung Hwa HanEugene Investment & Securities Co Ltd.Brian ChoHSBCSang-Hun LeeiM Securities5 その他のアナリストを表示
New Risk • May 21New major risk - Revenue and earnings growthEarnings have declined by 0.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.8% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (13% average weekly change).
お知らせ • Apr 25Caregen Co., Ltd. to Report Q1, 2026 Results on Apr 30, 2026Caregen Co., Ltd. announced that they will report Q1, 2026 results on Apr 30, 2026
Reported Earnings • Mar 20Full year 2025 earnings released: EPS: ₩411 (vs ₩658 in FY 2024)Full year 2025 results: EPS: ₩411 (down from ₩658 in FY 2024). Revenue: ₩72.8b (down 12% from FY 2024). Net income: ₩20.1b (down 38% from FY 2024). Profit margin: 28% (down from 39% in FY 2024). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 45% per year, which means it is well ahead of earnings.
お知らせ • Mar 10Caregen Co., Ltd., Annual General Meeting, Mar 24, 2026Caregen Co., Ltd., Annual General Meeting, Mar 24, 2026, at 09:30 Tokyo Standard Time. Location: conference room, 24, yeongdong-daero 65-gil, gangnam-gu, seoul South Korea
New Risk • Jan 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
New Risk • Nov 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
New Risk • May 21New major risk - Revenue and earnings growthEarnings have declined by 0.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.8% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (13% average weekly change).
お知らせ • Apr 25Caregen Co., Ltd. to Report Q1, 2026 Results on Apr 30, 2026Caregen Co., Ltd. announced that they will report Q1, 2026 results on Apr 30, 2026
Reported Earnings • Mar 20Full year 2025 earnings released: EPS: ₩411 (vs ₩658 in FY 2024)Full year 2025 results: EPS: ₩411 (down from ₩658 in FY 2024). Revenue: ₩72.8b (down 12% from FY 2024). Net income: ₩20.1b (down 38% from FY 2024). Profit margin: 28% (down from 39% in FY 2024). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 45% per year, which means it is well ahead of earnings.
お知らせ • Mar 10Caregen Co., Ltd., Annual General Meeting, Mar 24, 2026Caregen Co., Ltd., Annual General Meeting, Mar 24, 2026, at 09:30 Tokyo Standard Time. Location: conference room, 24, yeongdong-daero 65-gil, gangnam-gu, seoul South Korea
New Risk • Jan 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
New Risk • Nov 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
分析記事 • Nov 23There's Reason For Concern Over Caregen Co., Ltd.'s (KOSDAQ:214370) Massive 32% Price JumpDespite an already strong run, Caregen Co., Ltd. ( KOSDAQ:214370 ) shares have been powering on, with a gain of 32% in...
分析記事 • Sep 12Subdued Growth No Barrier To Caregen Co., Ltd. (KOSDAQ:214370) With Shares Advancing 26%Despite an already strong run, Caregen Co., Ltd. ( KOSDAQ:214370 ) shares have been powering on, with a gain of 26% in...
New Risk • Sep 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • Jul 30Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩50,400, the stock trades at a trailing P/E ratio of 78.9x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 90% over the past three years.
Valuation Update With 7 Day Price Move • Jul 15Investor sentiment improves as stock rises 28%After last week's 28% share price gain to ₩48,200, the stock trades at a trailing P/E ratio of 75.4x. Average trailing P/E is 18x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 159% over the past three years.
分析記事 • Jul 14Caregen Co., Ltd.'s (KOSDAQ:214370) 30% Jump Shows Its Popularity With InvestorsCaregen Co., Ltd. ( KOSDAQ:214370 ) shares have continued their recent momentum with a 30% gain in the last month...
分析記事 • Jul 14Why Investors Shouldn't Be Surprised By Caregen Co., Ltd.'s (KOSDAQ:214370) 30% Share Price SurgeCaregen Co., Ltd. ( KOSDAQ:214370 ) shares have continued their recent momentum with a 30% gain in the last month...
New Risk • Jul 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Dividend is not well covered by earnings and cash flows. Payout ratio: 100% Paying a dividend despite having no free cash flows. High level of non-cash earnings (73% accrual ratio).
Upcoming Dividend • Jun 20Upcoming dividend of ₩240 per shareEligible shareholders must have bought the stock before 27 June 2025. Payment date: 21 July 2025. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 2.0%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (1.0%).
分析記事 • May 22Caregen's (KOSDAQ:214370) Problems Go Beyond Weak ProfitThe market rallied behind Caregen Co., Ltd.'s ( KOSDAQ:214370 ) stock, leading do a rise in the share price after its...
New Risk • May 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 97% Paying a dividend despite having no free cash flows. High level of non-cash earnings (63% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).
Buy Or Sell Opportunity • May 12Now 25% overvaluedOver the last 90 days, the stock has fallen 1.5% to ₩30,550. The fair value is estimated to be ₩24,440, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 33%. Revenue is forecast to grow by 44% in 2 years. Earnings are forecast to grow by 89% in the next 2 years.
Board Change • Apr 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 1 highly experienced director. Independent Outside Director Seong-Wook Heo was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Mar 21Full year 2024 earnings: EPS misses analyst expectationsFull year 2024 results: EPS: ₩658 (down from ₩813 in FY 2023). Revenue: ₩82.6b (up 4.3% from FY 2023). Net income: ₩32.3b (down 19% from FY 2023). Profit margin: 39% (down from 50% in FY 2023). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.9%. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.
お知らせ • Mar 12Caregen Co., Ltd., Annual General Meeting, Mar 25, 2025Caregen Co., Ltd., Annual General Meeting, Mar 25, 2025, at 09:30 Tokyo Standard Time. Location: conference room, 16-27, ls-ro 91beon-gil, dongan-gu, gyeonggi-do, anyang South Korea
分析記事 • Mar 08Caregen Co., Ltd. (KOSDAQ:214370) May Have Run Too Fast Too Soon With Recent 26% Price PlummetCaregen Co., Ltd. ( KOSDAQ:214370 ) shares have retraced a considerable 26% in the last month, reversing a fair amount...
New Risk • Feb 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 121% Paying a dividend despite having no free cash flows. High level of non-cash earnings (68% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).
Buy Or Sell Opportunity • Feb 06Now 32% overvalued after recent price riseOver the last 90 days, the stock has risen 101% to ₩33,950. The fair value is estimated to be ₩25,767, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 28%. Revenue is forecast to grow by 45% in 2 years. Earnings are forecast to grow by 61% in the next 2 years.
お知らせ • Feb 03Caregen Co., Ltd. to Report Q4, 2024 Results on Feb 10, 2025Caregen Co., Ltd. announced that they will report Q4, 2024 results on Feb 10, 2025
分析記事 • Jan 20A Look At The Fair Value Of Caregen Co., Ltd. (KOSDAQ:214370)Key Insights Using the 2 Stage Free Cash Flow to Equity, Caregen fair value estimate is ₩25,767 Caregen's ₩28,100 share...
Buy Or Sell Opportunity • Jan 03Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 62% to ₩31,750. The fair value is estimated to be ₩25,767, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 28%. Revenue is forecast to grow by 45% in 2 years. Earnings are forecast to grow by 61% in the next 2 years.
Valuation Update With 7 Day Price Move • Dec 26Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩28,500, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 17x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 126% over the past three years.
分析記事 • Dec 20Earnings Not Telling The Story For Caregen Co., Ltd. (KOSDAQ:214370) After Shares Rise 29%Caregen Co., Ltd. ( KOSDAQ:214370 ) shares have continued their recent momentum with a 29% gain in the last month...
Valuation Update With 7 Day Price Move • Nov 21Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₩23,150, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 17x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 86% over the past three years.
分析記事 • Nov 21Why Caregen's (KOSDAQ:214370) Shaky Earnings Are Just The Beginning Of Its ProblemsDespite Caregen Co., Ltd.'s ( KOSDAQ:214370 ) recent earnings report having lackluster headline numbers, the market...
お知らせ • Nov 08Caregen Co., Ltd. to Report Q3, 2024 Results on Nov 11, 2024Caregen Co., Ltd. announced that they will report Q3, 2024 results on Nov 11, 2024
Valuation Update With 7 Day Price Move • Sep 13Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩18,550, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 19x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 33% over the past three years.
New Risk • Aug 26New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. Payout ratio: 93% The company is paying a dividend despite having no free cash flows. Dividend yield: 5.2% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 93% Paying a dividend despite having no free cash flows. High level of non-cash earnings (70% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).
Major Estimate Revision • Aug 06Consensus EPS estimates fall by 18%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from ₩93.0m to ₩85.1m. EPS estimate also fell from ₩907 per share to ₩747 per share. Net income forecast to grow 9.7% next year vs 21% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target down from ₩24,000 to ₩14,000. Share price fell 29% to ₩16,240 over the past week.
分析記事 • Aug 06Why We're Not Concerned Yet About Caregen Co., Ltd.'s (KOSDAQ:214370) 26% Share Price PlungeThe Caregen Co., Ltd. ( KOSDAQ:214370 ) share price has fared very poorly over the last month, falling by a substantial...
Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 28%After last week's 28% share price decline to ₩16,240, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 16x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 21% over the past three years.
New Risk • Aug 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (62% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.3% average weekly change).
お知らせ • Aug 01Caregen Co., Ltd. to Report First Half, 2024 Results on Aug 02, 2024Caregen Co., Ltd. announced that they will report first half, 2024 results on Aug 02, 2024
Reported Earnings • May 18First quarter 2024 earnings released: EPS: ₩194 (vs ₩288 in 1Q 2023)First quarter 2024 results: EPS: ₩194 (down from ₩288 in 1Q 2023). Revenue: ₩20.4b (down 17% from 1Q 2023). Net income: ₩9.52b (down 33% from 1Q 2023). Profit margin: 47% (down from 57% in 1Q 2023). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 19% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • May 01Caregen Co., Ltd. to Report Q1, 2024 Results on May 10, 2024Caregen Co., Ltd. announced that they will report Q1, 2024 results on May 10, 2024
分析記事 • Mar 18Caregen (KOSDAQ:214370) Posted Healthy Earnings But There Are Some Other Factors To Be Aware OfCaregen Co., Ltd. ( KOSDAQ:214370 ) just reported some strong earnings, and the market reacted accordingly with a...
Reported Earnings • Mar 15Full year 2023 earnings released: EPS: ₩813 (vs ₩556 in FY 2022)Full year 2023 results: EPS: ₩813 (up from ₩556 in FY 2022). Revenue: ₩79.2b (up 15% from FY 2022). Net income: ₩39.9b (up 46% from FY 2022). Profit margin: 50% (up from 40% in FY 2022). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 43% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Mar 12Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩26,200, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 15x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 111% over the past three years.
分析記事 • Mar 05With Caregen Co., Ltd. (KOSDAQ:214370) It Looks Like You'll Get What You Pay ForCaregen Co., Ltd.'s ( KOSDAQ:214370 ) price-to-earnings (or "P/E") ratio of 29.7x might make it look like a strong sell...
Valuation Update With 7 Day Price Move • Feb 13Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩25,350, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 16x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 92% over the past three years.
Upcoming Dividend • Dec 20Upcoming dividend of ₩340 per share at 2.0% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 05 April 2024. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 2.0%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.1%).
Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: ₩199 (vs ₩128 in 3Q 2022)Third quarter 2023 results: EPS: ₩199 (up from ₩128 in 3Q 2022). Revenue: ₩18.7b (up 2.2% from 3Q 2022). Net income: ₩9.80b (up 56% from 3Q 2022). Profit margin: 52% (up from 34% in 3Q 2022). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 41% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Pharmaceuticals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Nov 13Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₩24,000, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 13x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 101% over the past three years.
お知らせ • Nov 01Caregen Co., Ltd. to Report Q3, 2023 Results on Nov 10, 2023Caregen Co., Ltd. announced that they will report Q3, 2023 results on Nov 10, 2023
Valuation Update With 7 Day Price Move • Oct 10Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₩31,400, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 15x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 176% over the past three years.
Buying Opportunity • Sep 18Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 14%. The fair value is estimated to be ₩50,401, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.2% over the last 3 years. Earnings per share has declined by 29%. Revenue is forecast to grow by 123% in 2 years. Earnings is forecast to grow by 153% in the next 2 years.
Price Target Changed • Aug 25Price target increased by 7.4% to ₩58,000Up from ₩54,000, the current price target is provided by 1 analyst. New target price is 48% above last closing price of ₩39,250. Stock is up 56% over the past year. The company is forecast to post earnings per share of ₩946 for next year compared to ₩278 last year.
お知らせ • Jul 29Caregen Co., Ltd. to Report Q2, 2023 Results on Aug 09, 2023Caregen Co., Ltd. announced that they will report Q2, 2023 results on Aug 09, 2023
Buying Opportunity • Jul 03Now 24% undervaluedOver the last 90 days, the stock is up 10.0%. The fair value is estimated to be ₩310,506, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.9% over the last 3 years. Earnings per share has declined by 30%. Revenue is forecast to grow by 139% in 2 years. Earnings is forecast to grow by 171% in the next 2 years.
Upcoming Dividend • Jun 22Upcoming dividend of ₩1,000 per share at 1.2% yieldEligible shareholders must have bought the stock before 29 June 2023. Payment date: 20 July 2023. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 1.2%. Lower than top quartile of South Korean dividend payers (3.2%). In line with average of industry peers (1.2%).
New Risk • Jun 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 156% Cash payout ratio: 119% Minor Risk Share price has been volatile over the past 3 months (8.3% average weekly change).
Valuation Update With 7 Day Price Move • Jun 16Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩227,500, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 12x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 233% over the past three years.
Reported Earnings • May 10First quarter 2023 earnings released: EPS: ₩1,440 (vs ₩768 in 1Q 2022)First quarter 2023 results: EPS: ₩1,440 (up from ₩768 in 1Q 2022). Revenue: ₩24.7b (up 61% from 1Q 2022). Net income: ₩14.1b (up 88% from 1Q 2022). Profit margin: 57% (up from 49% in 1Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has increased by 54% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩213,500, the stock trades at a trailing P/E ratio of 76.9x. Average trailing P/E is 20x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 117% over the past year.
Valuation Update With 7 Day Price Move • Mar 21Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩201,500, the stock trades at a trailing P/E ratio of 72.6x. Average trailing P/E is 20x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 249% over the past year.
Reported Earnings • Mar 18Full year 2022 earnings released: EPS: ₩2,778 (vs ₩2,582 in FY 2021)Full year 2022 results: EPS: ₩2,778 (up from ₩2,582 in FY 2021). Revenue: ₩69.1b (up 17% from FY 2021). Net income: ₩27.3b (up 7.7% from FY 2021). Profit margin: 40% (down from 43% in FY 2021). The decrease in margin was driven by higher expenses.
Valuation Update With 7 Day Price Move • Feb 01Investor sentiment improves as stock rises 28%After last week's 28% share price gain to ₩180,000, the stock trades at a trailing P/E ratio of 68.7x. Average trailing P/E is 20x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 189% over the past year.
Valuation Update With 7 Day Price Move • Dec 27Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₩145,000, the stock trades at a trailing P/E ratio of 55.4x. Average trailing P/E is 21x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 126% over the past year.
Upcoming Dividend • Dec 21Upcoming dividend of ₩1,500 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 17 April 2023. The company is paying out more than 100% of its profits and is paying out 75% of its cash flow. Trailing yield: 2.0%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (1.0%).
Valuation Update With 7 Day Price Move • Dec 05Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₩128,100, the stock trades at a trailing P/E ratio of 48.9x. Average trailing P/E is 19x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 104% over the past year.
Reported Earnings • Nov 16Third quarter 2022 earnings released: EPS: ₩640 (vs ₩669 in 3Q 2021)Third quarter 2022 results: EPS: ₩640 (down from ₩669 in 3Q 2021). Revenue: ₩18.3b (up 34% from 3Q 2021). Net income: ₩6.28b (down 4.3% from 3Q 2021). Profit margin: 34% (down from 48% in 3Q 2021). The decrease in margin was driven by higher expenses.
Reported Earnings • Nov 13Third quarter 2022 earnings released: EPS: ₩640 (vs ₩669 in 3Q 2021)Third quarter 2022 results: EPS: ₩640 (down from ₩669 in 3Q 2021). Revenue: ₩18.3b (up 34% from 3Q 2021). Net income: ₩6.28b (down 4.3% from 3Q 2021). Profit margin: 34% (down from 48% in 3Q 2021). The decrease in margin was driven by higher expenses.
Valuation Update With 7 Day Price Move • Nov 07Investor sentiment improved over the past weekAfter last week's 27% share price gain to ₩116,900, the stock trades at a trailing P/E ratio of 44.1x. Average trailing P/E is 21x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 80% over the past year.
Valuation Update With 7 Day Price Move • Oct 21Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩95,600, the stock trades at a trailing P/E ratio of 36x. Average trailing P/E is 20x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 40% over the past year.
Valuation Update With 7 Day Price Move • Sep 28Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩119,400, the stock trades at a trailing P/E ratio of 45x. Average trailing P/E is 19x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 73% over the past year.
Valuation Update With 7 Day Price Move • Sep 06Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩144,400, the stock trades at a trailing P/E ratio of 54.4x. Average trailing P/E is 22x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 98% over the past year.
Valuation Update With 7 Day Price Move • Jul 20Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩110,500, the stock trades at a trailing P/E ratio of 43.1x. Average trailing P/E is 22x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 68% over the past year.
Upcoming Dividend • Jun 22Upcoming dividend of ₩800 per shareEligible shareholders must have bought the stock before 29 June 2022. Payment date: 20 July 2022. Payout ratio is on the higher end at 90%, however this is supported by cash flows. Trailing yield: 2.5%. Lower than top quartile of South Korean dividend payers (3.2%). Higher than average of industry peers (1.0%).
Valuation Update With 7 Day Price Move • May 06Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to ₩104,000, the stock trades at a trailing P/E ratio of 40.3x. Average trailing P/E is 27x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 71% over the past year.
Valuation Update With 7 Day Price Move • Apr 13Investor sentiment improved over the past weekAfter last week's 31% share price gain to ₩126,000, the stock trades at a trailing P/E ratio of 48.8x. Average trailing P/E is 26x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 82% over the past three years.
Valuation Update With 7 Day Price Move • Mar 29Investor sentiment improved over the past weekAfter last week's 40% share price gain to ₩97,200, the stock trades at a trailing P/E ratio of 37.6x. Average trailing P/E is 25x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 40% over the past three years.
Valuation Update With 7 Day Price Move • Mar 15Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩65,000, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 23x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 6.1% over the past three years.
Upcoming Dividend • Dec 22Upcoming dividend of ₩1,300 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 11 April 2022. Payout ratio is on the higher end at 87%, however this is supported by cash flows. Trailing yield: 2.4%. Within top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.8%).
Upcoming Dividend • Jun 23Upcoming dividend of ₩700 per shareEligible shareholders must have bought the stock before 29 June 2021. Payment date: 24 July 2021. Trailing yield: 3.0%. Within top quartile of South Korean dividend payers (2.1%). Higher than average of industry peers (0.6%).
分析記事 • Apr 20A Look At The Fair Value Of Caregen Co., Ltd. (KOSDAQ:214370)In this article we are going to estimate the intrinsic value of Caregen Co., Ltd. ( KOSDAQ:214370 ) by taking the...
分析記事 • Mar 02Here's How We Evaluate Caregen Co., Ltd.'s (KOSDAQ:214370) DividendDividend paying stocks like Caregen Co., Ltd. ( KOSDAQ:214370 ) tend to be popular with investors, and for good reason...
分析記事 • Feb 04Caregen (KOSDAQ:214370) Is Growing Earnings But Are They A Good Guide?Statistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. However...
お知らせ • Jan 31Caregen Co., Ltd. to Report Fiscal Year 2020 Results on Feb 10, 2021Caregen Co., Ltd. announced that they will report fiscal year 2020 results on Feb 10, 2021
分析記事 • Jan 14Do Its Financials Have Any Role To Play In Driving Caregen Co., Ltd.'s (KOSDAQ:214370) Stock Up Recently?Most readers would already be aware that Caregen's (KOSDAQ:214370) stock increased significantly by 28% over the past...
Is New 90 Day High Low • Jan 05New 90-day high: ₩76,300The company is up 23% from its price of ₩62,200 on 07 October 2020. The South Korean market is also up 23% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Pharmaceuticals industry, which is up 16% over the same period.
分析記事 • Dec 25Caregen Co., Ltd. (KOSDAQ:214370) Goes Ex-Dividend SoonIt looks like Caregen Co., Ltd. ( KOSDAQ:214370 ) is about to go ex-dividend in the next three days. Ex-dividend means...
分析記事 • Dec 10Do Insiders Own Lots Of Shares In Caregen Co., Ltd. (KOSDAQ:214370)?Every investor in Caregen Co., Ltd. ( KOSDAQ:214370 ) should be aware of the most powerful shareholder groups...
Is New 90 Day High Low • Dec 09New 90-day high: ₩71,400The company is up 11% from its price of ₩64,100 on 10 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 6.0% over the same period.
Is New 90 Day High Low • Nov 20New 90-day high: ₩66,400The company is up 8.0% from its price of ₩61,700 on 21 August 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 5.0% over the same period.
分析記事 • Nov 19Is Caregen Co., Ltd. (KOSDAQ:214370) A Great Dividend Stock?Could Caregen Co., Ltd. (KOSDAQ:214370) be an attractive dividend share to own for the long haul? Investors are often...
Is New 90 Day High Low • Oct 15New 90-day low: ₩60,400The company is down 14% from its price of ₩69,900 on 17 July 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 12% over the same period.
